Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

home / authors / mark-freedman-md

Professor of Medicine in Neurology, University of Ottawa; Director, Multiple Sclerosis Research Unit, Ottawa Hospital; Senior Scientist, Ottawa Hospital Research Institute

Articles

Misdiagnosis of Multiple Sclerosis

Fred Lublin, MD;Patricia K. Coyle, MD;Scott Newsome, DO, MSCS, FAAN;Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

December 25th 2020

Use of MRI in Diagnosing Multiple Sclerosis

Fred Lublin, MD;Patricia K. Coyle, MD;Scott Newsome, DO, MSCS, FAAN;Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

December 23rd 2020

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

Fred Lublin, MD;Patricia K. Coyle, MD;Scott Newsome, DO, MSCS, FAAN;Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

December 16th 2020

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

CLARITY Extension Trial: Disability Improvement With Cladribine

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC;Robert Naismith, MD;Bianca Weinstock-Guttman, MD

November 24th 2020

Mark Freedman, MD: An Update on Stem Cell Research in MS

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

May 22nd 2020

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CIS

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

March 28th 2019

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the results of BENEFIT 15 that support early intervention of interferon beta-1b treatment at or shortly after CIS.

Mark Freedman, MD: Precision Medicine in Multiple Sclerosis

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

March 24th 2019

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the need for clinicians to select the right patient for the right treatment in the MS clinic.

Mark Freedman, MD: Long-Term Efficacy and Safety Studies in MS

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

March 9th 2019

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the importance of long-term efficacy studies.

<1 2